Loading...
Loading...
Browse all stories on DeepNewz
VisitEisai and Biogen Begin Rolling BLA for Subcutaneous, Injectable Alzheimer's Drug Leqembi
May 15, 2024, 04:15 AM
Eisai and Biogen have initiated a rolling Biologics License Application (BLA) to the U.S. FDA for a subcutaneous, injectable version of their Alzheimer's drug, Leqembi. This submission, which had been delayed due to procedural issues, aims to provide a maintenance dosing option for early Alzheimer's disease. The application is being processed under the FDA's Fast Track status, which is designed to expedite the review of drugs that treat serious conditions and fill an unmet medical need.
View original story
Markets
Yes • 50%
No • 50%
Official announcement by the U.S. FDA or news release from Eisai and Biogen
Yes • 50%
No • 50%
Press releases from Eisai and Biogen or major health news outlets
No • 50%
Yes • 50%
Public disclosures by pharmaceutical companies or FDA new drug application announcements
Marginally better than existing treatments • 25%
Significantly better than existing treatments • 25%
Underperforms existing treatments • 25%
Equivalent to existing treatments • 25%
Clinical study reports, medical journals, and health news outlets
Applications in Europe • 25%
No applications • 25%
Applications in South America • 25%
Applications in Asia • 25%
Corporate announcements from Eisai and Biogen, international health regulatory updates
Little to no change (<5%) • 25%
Moderate stock price increase (5-15%) • 25%
Significant stock price increase (>15%) • 25%
Stock price decrease • 25%
Stock market data and financial news outlets